Stock Screener
Stock Research
Delisted Stocks
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Ironwood Pharmaceuticals Shares Outstanding 2010-2023 | IRWD

Ironwood Pharmaceuticals shares outstanding from 2010 to 2023. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  
Ironwood Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2023 155
2022 186
2021 164
2020 161
2019 156
2018 153
2017 149
2016 145
2015 142
2014 137
2013 116
2012 106
2011 100
2010 90
2009 7
Ironwood Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
2023-12-31 155
2023-09-30 187
2023-06-30 155
2023-03-31 187
2022-12-31 186
2022-09-30 184
2022-06-30 185
2022-03-31 190
2021-12-31 164
2021-09-30 165
2021-06-30 163
2021-03-31 162
2020-12-31 161
2020-09-30 160
2020-06-30 160
2020-03-31 160
2019-12-31 156
2019-09-30 157
2019-06-30 156
2019-03-31 155
2018-12-31 153
2018-09-30 153
2018-06-30 152
2018-03-31 151
2017-12-31 149
2017-09-30 150
2017-06-30 149
2017-03-31 148
2016-12-31 145
2016-09-30 145
2016-06-30 145
2016-03-31 144
2015-12-31 142
2015-09-30 142
2015-06-30 142
2015-03-31 141
2014-12-31 137
2014-09-30 139
2014-06-30 138
2014-03-31 130
2013-12-31 116
2013-09-30 121
2013-06-30 113
2013-03-31 108
2012-12-31 106
2012-09-30 114
2012-06-30 107
2012-03-31 104
2011-12-31 100
2011-09-30 100
2011-06-30 100
2011-03-31 99
2010-12-31 90
2010-09-30 98
2010-06-30 98
2010-03-31 64
2009-12-31 7
2009-09-30 7
2009-06-30 7
2009-03-31 7
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $1.047B $0.443B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $76.617B 31.15
Chugai Pharmaceutical (CHGCY) Japan $51.784B 23.15
Takeda Pharmaceutical (TAK) Japan $41.491B 8.40
Merck (MKGAF) Germany $21.235B 20.04
Astellas Pharma (ALPMY) Japan $17.409B 27.49
Sandoz Group AG (SDZNY) Switzerland $15.266B 0.00
Shionogi (SGIOY) Japan $14.400B 12.52
Neurocrine Biosciences (NBIX) United States $13.702B 37.51
United Therapeutics (UTHR) United States $11.725B 12.50
Catalent (CTLT) United States $10.099B 0.00
Cerevel Therapeutics Holdings (CERE) United States $7.637B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.134B 7.84
Revolution Medicines (RVMD) United States $6.133B 0.00
Ionis Pharmaceuticals (IONS) United States $5.663B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.396B 0.00
Orion OYJ (ORINY) Finland $4.940B 20.83
Madrigal Pharmaceuticals (MDGL) United States $4.504B 0.00
Alpine Immune Sciences (ALPN) United States $4.455B 0.00
Crinetics Pharmaceuticals (CRNX) United States $3.780B 0.00
Summit Therapeutics (SMMT) United States $3.370B 0.00
Corcept Therapeutics (CORT) United States $2.866B 25.97
Arrowhead Pharmaceuticals (ARWR) United States $2.740B 0.00
Indivior (INDV) United States $2.464B 11.68
PTC Therapeutics (PTCT) United States $2.431B 0.00
Dyne Therapeutics (DYN) United States $2.326B 0.00
Recursion Pharmaceuticals (RXRX) United States $2.225B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.060B 11.77
Catalyst Pharmaceuticals (CPRX) United States $1.916B 18.64
Evotec AG (EVO) Germany $1.896B 0.00
Ardelyx (ARDX) United States $1.866B 0.00
Fusion Pharmaceuticals (FUSN) Canada $1.823B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $1.804B 0.00
Taro Pharmaceutical Industries (TARO) Israel $1.586B 27.76
Avadel Pharmaceuticals (AVDL) Ireland $1.523B 0.00
Soleno Therapeutics (SLNO) United States $1.430B 0.00
Pacira BioSciences (PCRX) United States $1.414B 13.44
4D Molecular Therapeutics (FDMT) United States $1.322B 0.00
Xencor (XNCR) United States $1.316B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.162B 0.00
Enliven Therapeutics (ELVN) United States $1.151B 0.00
Cronos Group (CRON) Canada $1.119B 0.00
Collegium Pharmaceutical (COLL) United States $1.052B 6.29
Cassava Sciences (SAVA) United States $0.989B 0.00
USANA Health Sciences (USNA) United States $0.901B 14.73
Centessa Pharmaceuticals (CNTA) United Kingdom $0.890B 0.00
Ocular Therapeutix (OCUL) United States $0.874B 0.00
ARS Pharmaceuticals (SPRY) United States $0.861B 0.00
Relay Therapeutics (RLAY) United States $0.852B 0.00
Sage Therapeutics (SAGE) United States $0.732B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.716B 0.00
ProKidney (PROK) United States $0.706B 0.00
Savara (SVRA) United States $0.634B 0.00
Calliditas Therapeutics AB (CALT) Sweden $0.626B 0.00
Silence Therapeutics (SLN) United Kingdom $0.623B 0.00
Lyell Immunopharma (LYEL) United States $0.612B 0.00
Exscientia (EXAI) United Kingdom $0.594B 0.00
Siga Technologies (SIGA) United States $0.530B 6.77
OmniAb (OABI) United States $0.525B 0.00
Altimmune (ALT) United States $0.523B 0.00
Verve Therapeutics (VERV) United States $0.522B 0.00
KalVista Pharmaceuticals (KALV) United States $0.506B 0.00
Larimar Therapeutics (LRMR) United States $0.467B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.465B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.458B 0.00
Bioventus (BVS) United States $0.453B 17.33
Lexeo Therapeutics (LXEO) United States $0.447B 0.00
Harrow (HROW) United States $0.427B 0.00
Heron Therapeutics (HRTX) United States $0.424B 0.00
Esperion Therapeutics (ESPR) United States $0.423B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.406B 0.00
Korro Bio (KRRO) United States $0.403B 0.00
Organogenesis (ORGO) United States $0.392B 74.00
Tourmaline Bio (TRML) United States $0.370B 0.00
Black Diamond Therapeutics (BDTX) United States $0.334B 0.00
Nanobiotix S.A (NBTX) France $0.323B 0.00
Nektar Therapeutics (NKTR) United States $0.321B 0.00
Aquestive Therapeutics (AQST) United States $0.298B 0.00
Fractyl Health (GUTS) United States $0.292B 0.00
Nature's Sunshine Products (NATR) United States $0.291B 18.46
Xeris Biopharma Holdings (XERS) United States $0.280B 0.00
Adherex Technologies (FENC) United States $0.274B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.273B 0.00
Akebia Therapeutics (AKBA) United States $0.270B 0.00
ESSA Pharma (EPIX) Canada $0.262B 0.00
Pyxis Oncology (PYXS) United States $0.253B 0.00
Metagenomi (MGX) United States $0.245B 0.00
Foghorn Therapeutics (FHTX) United States $0.241B 0.00
Eliem Therapeutics (ELYM) United States $0.233B 0.00
Conduit Pharmaceuticals (CDT) United States $0.228B 0.00
Aldeyra Therapeutics (ALDX) United States $0.220B 0.00
Avita Medical (RCEL) United States $0.215B 0.00
Zevra Therapeutics (ZVRA) United States $0.205B 0.00
Telomir Pharmaceuticals (TELO) United States $0.197B 0.00
Century Therapeutics (IPSC) United States $0.194B 0.00
Acrivon Therapeutics (ACRV) United States $0.192B 0.00
Galectin Therapeutics (GALT) United States $0.191B 0.00
Profound Medical (PROF) Canada $0.187B 0.00
Innate Pharma SA (IPHYF) France $0.176B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.172B 0.00
MediWound (MDWD) Israel $0.168B 0.00
Incannex Healthcare (IXHL) Australia $0.166B 0.00
Achieve Life Sciences (ACHV) Canada $0.165B 0.00
Prelude Therapeutics (PRLD) United States $0.160B 0.00
Cardiol Therapeutics (CRDL) Canada $0.149B 0.00
CytoDyn (CYDY) United States $0.146B 0.00
VAXART, INC (VXRT) United States $0.145B 0.00
Elite Pharmaceuticals (ELTP) United States $0.145B 13.56
Regulus Therapeutics (RGLS) United States $0.137B 0.00
OptiNose (OPTN) United States $0.132B 0.00
Karyopharm Therapeutics (KPTI) United States $0.132B 0.00
Context Therapeutics (CNTX) United States $0.126B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.124B 8.27
FibroGen (FGEN) United States $0.120B 0.00
Citius Pharmaceuticals (CTXR) United States $0.111B 0.00
PMV Pharmaceuticals (PMVP) United States $0.110B 0.00
Inotiv (NOTV) United States $0.108B 0.00
Relmada Therapeutics (RLMD) United States $0.107B 0.00
Vivani Medical (VANI) United States $0.102B 0.00
ProPhase Labs (PRPH) United States $0.101B 0.00
Assertio Holdings (ASRT) United States $0.100B 4.57
AlloVir (ALVR) United States $0.086B 0.00
ARYA Sciences Acquisition Corp IV (ARYD) United States $0.086B 0.00
Aclaris Therapeutics (ACRS) United States $0.084B 0.00
Jaguar Animal Health (JAGX) United States $0.080B 0.00
SCYNEXIS (SCYX) United States $0.077B 1.09
Marinus Pharmaceuticals (MRNS) United States $0.074B 0.00
Tempest Therapeutics (TPST) United States $0.073B 0.00
Journey Medical (DERM) United States $0.071B 0.00
Protara Therapeutics (TARA) United States $0.067B 0.00
Champions Oncology (CSBR) United States $0.064B 0.00
Mural Oncology (MURA) Ireland $0.063B 0.00
Carisma Therapeutics (CARM) United States $0.061B 0.00
Reneo Pharmaceuticals (RPHM) United States $0.053B 0.00
BioLineRx (BLRX) Israel $0.050B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.047B 0.00
Gain Therapeutics (GANX) United States $0.044B 0.00
ElectroCore (ECOR) United States $0.044B 0.00
VYNE Therapeutics (VYNE) United States $0.041B 0.00
Unicycive Therapeutics (UNCY) United States $0.041B 0.00
Natural Alternatives (NAII) United States $0.040B 0.00
Nutriband (NTRB) United States $0.040B 0.00
Rafael Holdings (RFL) United States $0.039B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.036B 0.00
JanOne (JAN) United States $0.034B 0.00
CASI Pharmaceuticals (CASI) China $0.034B 0.00
DURECT (DRRX) United States $0.033B 0.00
Surrozen (SRZN) United States $0.033B 0.00
NRx Pharmaceuticals (NRXP) United States $0.032B 0.00
Viracta Therapeutics (VIRX) United States $0.030B 0.00
Lipocine (LPCN) United States $0.028B 0.00
Aptorum Group (APM) United Kingdom $0.027B 0.00
Enlivex Therapeutics (ENLV) Israel $0.027B 0.00
Oncternal Therapeutics (ONCT) United States $0.025B 0.00
Iterum Therapeutics (ITRM) Ireland $0.025B 0.00
TherapeuticsMD (TXMD) United States $0.024B 0.00
PolyPid (PYPD) Israel $0.023B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.023B 0.00
Lyra Therapeutics (LYRA) United States $0.022B 0.00
MEI Pharma (MEIP) United States $0.021B 0.80
Alaunos Therapeutics (TCRT) United States $0.020B 0.00
BioVie (BIVI) United States $0.019B 0.00
Indaptus Therapeutics (INDP) United States $0.018B 0.00
Nuvilex (PMCB) United States $0.018B 0.00
Talphera (TLPH) United States $0.018B 0.00
CERo Therapeutics Holdings (CERO) United States $0.017B 0.00
Minerva Neurosciences (NERV) United States $0.017B 0.00
GlycoMimetics (GLYC) United States $0.017B 0.00
Traws Pharma (TRAW) United States $0.016B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.016B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.014B 0.00
Mannatech (MTEX) United States $0.014B 0.00
Redhill Biopharma (RDHL) Israel $0.014B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.013B 0.00
Dominari Holdings (DOMH) United States $0.012B 0.00
Cosmos Health (COSM) Greece $0.012B 0.00
Avalo Therapeutics (AVTX) United States $0.011B 0.00
Biomerica (BMRA) United States $0.010B 0.00
Addex Therapeutics (ADXN) Switzerland $0.010B 0.00
Plus Therapeutics (PSTV) United States $0.009B 0.00
Molecular Templates (MTEM) United States $0.009B 0.00
Inhibikase Therapeutics (IKT) United States $0.009B 0.00
Universe Pharmaceuticals INC (UPC) China $0.008B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.007B 0.00
Ainos (AIMD) United States $0.007B 0.00
Heatwurx (PCSA) United States $0.006B 0.00
Mangoceuticals (MGRX) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Vivos Therapeutics (VVOS) United States $0.006B 0.00
MyMD Pharmaceuticals (MYMD) United States $0.005B 0.00
XORTX Therapeutics (XRTX) Canada $0.005B 0.00
SHINECO (SISI) China $0.005B 0.00
Petros Pharmaceuticals (PTPI) United States $0.004B 0.00
Clever Leaves Holdings (CLVR) Canada $0.004B 0.00
TransCode Therapeutics (RNAZ) United States $0.004B 0.00
Phio Pharmaceuticals (PHIO) United States $0.003B 0.00
Finch Therapeutics (FNCH) United States $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.002B 0.00
Avenue Therapeutics (ATXI) United States $0.002B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
Bio-Path Holdings (BPTH) United States $0.002B 0.00
InMed Pharmaceuticals (INM) Canada $0.002B 0.00
Qualigen Therapeutics (QLGN) United States $0.002B 0.00
PainReform (PRFX) Israel $0.002B 0.00
SciSparc (SPRC) Israel $0.001B 0.00
Aditxt (ADTX) United States $0.000B 0.00
China SXT Pharmaceuticals (SXTC) China $0.000B 0.00
Qilian Holding Group (QLI) China $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 5.29
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 38.29